Amarin Corporation Plc

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amarin reports robust Q4 earnings, eyes global expansion opportunities

Amarin's Q4 2022 earnings call highlighted strong financial performance, successful global expansion efforts, and a focus on cash preservation and talent acquisition. The company's UK launch milestones and international progress position it well for future growth.

Amarin reports Q1 revenue growth amidst pricing challenges and opportunities

Amarin focuses on revenue growth and cost-saving initiatives to drive operational efficiency and profitability.
The company's strong cash position provides stability for future growth initiatives and strategic investments.
Challenges include pricing pressure from generics and the need to balance expenses with revenue growth.
Opportunities lie in expanding prescription growth, product portfolio, and exploring strategic partnerships.

Amarin Corporation Plc reports robust Q3 earnings and strategic growth plans

Amarin Corporation Plc's Q3 2023 earnings call showcased strong financial performance, operational decisions driving positive cash flow, and a focus on maximizing shareholder value. While challenges in the European market and uncertainties around stock price were noted, opportunities for growth in global markets and strategic initiatives offer potential for future success.

Amarin reports solid Q4 revenue growth and eyes global expansion

Amarin's Q4 2023 performance reflects revenue growth and ongoing investment in strategic initiatives.
The company's strong financial position and operational momentum in key markets position it well for future growth.
Challenges around market dynamics, expenses management, and competition require strategic focus for sustained success.

Amarin reports stable Q1 earnings, focuses on European growth opportunities

Amarin Corporation's Q1 2024 earnings call highlighted solid financial performance, successful IP defense in Europe, and positive clinical outcomes for its key products. While facing challenges in the U.S. market due to generic competition, the company maintains profitability and a strong cash position. Opportunities lie in shareholder value enhancement and continued growth in Europe.

Amarin reports stable revenue but faces generic competition challenges

Amarin's Q2 2024 performance reflects revenue decline in the U.S. due to generic competition but improved net income from expense reductions. The company's strengths lie in the success of Vascepa/VAZKEPA and maintaining market share. Challenges include adapting to changing market dynamics, while opportunities exist in global expansion and strategic initiatives.

Amarin reports Q3 revenue of $42.3M, focuses on global expansion

Amarin's Q3 2024 performance reflects a mixed financial outcome with total net revenue of $42.3M and a GAAP net loss of $25.1M, impacted by challenges in the U.S. generic market.
Despite facing pricing pressures and cost reduction efforts, the company maintains a stable cash position of $306M and remains focused on global expansion.
The strengths lie in the proven science and support for VASCEPA/VAZKEPA, with opportunities to address the unmet need in reducing cardiovascular disease globally.
Challenges include navigating market dynamics and maintaining profitability amidst pricing pressures, while upcoming events signal proactive engagement for long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corporation plc (NASDAQ: AMRN) shares are plunging after it said it would continue suspending 2022 revenue guidance and Q1 earnings came short of expectations. The update follows the ongoing global impact of COVID-19 and the uncertainty resulting from the impact of generic icosapent.

Why Amarin Shares Are Plunging After Q1 Earnings

Initiated Next Phase of European Expansion Strategy with First National Reimbursement in Sweden

Amarin Reports First Quarter 2022 Financial Results and Provides Business Update

The latest prespecified and post hoc sub-analysis of the landmark REDUCE-IT ® study, published today in the Journal of the American College of Cardiology (JACC), demonstrated that VASCEPA ® (icosapent ethyl) significantly reduces the total ischemic event risk of cardiovascular death, stroke, myocardial infarction (heart attack), coronary revascularization, or hospitalization for unstable angina by 35% in patients who had a prior heart attack. ( 1 )

New Analysis Reveals Icosapent Ethyl Significantly Reduces Risk of Major Cardiovascular Events in Patients with Prior Myocardial Infarction (Heart Attack)

DUBLIN, Ireland and BRIDGEWATER, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today its partner HLS Therapeutics has completed negotiations with Canada's pan-Canadian Pharmaceutical Alliance (pCPA) for the terms and conditions under which VASCEPA® (icosapent ethyl) would qualify for public market reimbursement in Canada. Following these negotiations, HLS has signed a Letter of Intent (LOI) which allows HLS to work with all participating provincial jurisdictions to secure coverage from publicly funded drug plans across Canada, and for VASCEPA to potentially be added to their respective plans.

Amarin Partner HLS Therapeutics Completes Reimbursement Negotiations with Pan-Canadian Pharmaceutical Alliance (pCPA) for VASCEPA® (icosapent ethyl)

Amarin has had a rough go of it since the patent ruling in the United States for their flagship product, Vascepa. The company is struggling to maintain growth as generics. The company is banking on the European markets to drive growth in the coming years. U.S. generics might have a hard time taking Vascepa's market share.

Amarin Corp.: Hitting The Thesis Reset Button

There are a number of interesting developments at Amarin. These may enable Amarin to regain ground it lost due to an unconscionable court ruling a few years ago.

Amarin: Alex Denner, Health Net, Statin Combo, And Signs Of Better Times

DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin's senior management team to discuss the Company's first quarter 2022 financial results on Wednesday, May 4, 2022 at 8:00 a.m. ET. The conference call will follow the anticipated release of the Company's financial results earlier that day.

Amarin to Report First Quarter 2022 Financial Results and Host Conference Call On May 4, 2022

Experimental trial research presented at the American College of Cardiology's 71st Annual Scientific Session showed that the combinations of EPA/atorvastatin active metabolite (ATM) and of EPA/rosuvastatin (rosuva) reduced lipid oxidation by 86% and 75%, respectively (p

Eicosapentaenoic Acid (EPA) Combined with Widely Used Statins Significantly Reduced Lipid Oxidation in Model Membranes

Marks First Health Technology Assessment (HTA) Reimbursement in Europe and Initiation of Next Phase of the Company's Growth Strategy

Amarin Receives Reimbursement for VAZKEPA® in Sweden

Amarin-Supported Research and Analyses to Be Featured in Six Presentations Amarin-Supported Research and Analyses to Be Featured in Six Presentations

Latest Research Evaluating VASCEPA® (Icosapent Ethyl) to be Presented at the American College of Cardiology's 71st Annual Scientific Session

A new post hoc sub-analysis of the landmark REDUCE-IT Study, published in the Journal of the American Heart Association (JAHA), found VASCEPA® significantly reduced the risk of cardiovascular death, strokes, heart attacks, coronary revascularization, and unstable angina by 34% in patients with a history of percutaneous coronary intervention (PCI). ( 1 )

Latest analysis shows VASCEPA® (icosapent ethyl) significantly lowered the risk of potentially fatal cardiovascular events in patients with prior percutaneous coronary intervention

Cowen

Amarin Corporation plc (AMRN) CEO Karim Mikhail on Cowen 42nd Annual Health Care Conference (Transcript)

Amarin's (AMRN) Vascepa sales decline amid rising generic competition and COVID-19 related disruptions during the fourth quarter. The company's stock falls on Mar 1, following the earnings release.

Amarin (AMRN) Q4 Earnings Top, Sales Hurt by Vascepa Generics

Amarin Corporation plc (AMRN) CEO Karim Mikhail on Q4 2021 Results - Earnings Call Transcript

Go-to-Market Strategy in U.S. to Optimize Provider Engagement and Drive Demand for VASCEPA®

Amarin Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Karim Mikhail, president and chief executive officer of Amarin, is scheduled to participate virtually in a fireside chat at the Cowen 42nd Annual Health Care Conference on Monday, March 7 from 9:10 AM – 9:40 AM ET.

Amarin to Participate in Cowen 42nd Annual Health Care Conference

Extensive analysis for U.S. by MedStar Health Research Institute determined icosapent ethyl is cost-effective compared to standard of care, both during the REDUCE-IT® clinical trial period and over a lifetime projection Extensive analysis for U.S. by MedStar Health Research Institute determined icosapent ethyl is cost-effective compared to standard of care, both during the REDUCE-IT® clinical trial period and over a lifetime projection

JAMA Publication Highlights VASCEPA® (Icosapent Ethyl) Cardiovascular Risk Reduction Extends to Cost Effectiveness at Patient Level

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Amarin (AMRN) is a Top-Ranked Growth Stock: Should You Buy?

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin's senior management team to discuss the Company's fourth quarter and full year 2021 financial results on Tuesday, March 1, 2022 at 8:00 a.m. ET. The conference call will follow the anticipated release of the Company's financial results earlier that day.

Amarin to Report Fourth Quarter and Full Year 2021 Financial Results And Host Conference Call on March 1, 2022

Globalstar

Kosmos Energy

Which penny stocks are on your watchlist for next month? The post 3 Penny Stocks to Add to Your Watchlist This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks to Add to Your Watchlist This Week

Activist fund Sarissa brings extensive knowledge and deep contacts in the health-care space, which could come in handy at Amarin.

Pharma company Amarin has a key asset and a big decision. How Sarissa Capital can help it move forward

The biopharma couldn't escape the market-wide downturn this week.

Why Amarin Stock Is Tumbling This Week

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Amarin (AMRN) is a Top Momentum Stock for the Long-Term

Southwestern Energy

Why these penny stocks climbed during trading today The post Should These Penny Stocks Be On Your February Watchlist? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Should These Penny Stocks Be On Your February Watchlist?

Vinco Ventures

Camber Energy

Here's three penny stocks that climbed today The post These Hot Penny Stocks Are Climbing While the Stock Market is Down appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Amarin Corporation Plc Stock (AMRN)